{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T03:36:52Z","timestamp":1789270612757,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Middle \/ Young aged Teachers' Research Ability Improvement Project of Guangxi Higher Education","award":["2024KY0102"],"award-info":[{"award-number":["2024KY0102"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"DOI":"10.1007\/s12026-026-09777-z","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:10:31Z","timestamp":1777601431000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["ANKFN1 in skin fibroblasts may modulate mast cell activity and is associated with dupilumab response in atopic dermatitis"],"prefix":"10.1007","volume":"74","author":[{"given":"Qiu-ju","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-rong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-yan","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-qi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-yu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-wen","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze-feng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-ju","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-jun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"key":"9777_CR1","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","volume":"387","author":"S Weidinger","year":"2016","unstructured":"Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387:1109\u201322.","journal-title":"Lancet"},{"key":"9777_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/bjd\/ljad339","volume":"190","author":"J Tian","year":"2023","unstructured":"Tian J, Zhang D, Yang Y, Huang Y, Wang L, Yao X, et al. Global epidemiology of atopic dermatitis: a comprehensive systematic analysis and modelling study. Br J Dermatol. 2023;190:55\u201361.","journal-title":"Br J Dermatol"},{"key":"9777_CR3","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/s12016-021-08880-3","volume":"61","author":"H Li","year":"2021","unstructured":"Li H, Zhang Z, Zhang H, Guo Y, Yao Z. Update on the pathogenesis and therapy of atopic dermatitis. Clin Rev Allergy Immunol. 2021;61:324\u201338.","journal-title":"Clin Rev Allergy Immunol"},{"key":"9777_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jid.2016.07.012","volume":"137","author":"AM Drucker","year":"2017","unstructured":"Drucker AM, Wang AR, Li WQ, Sevetson E, Block JK, Qureshi AA. The burden of atopic dermatitis: summary of a report for the national eczema association. J Invest Dermatol. 2017;137:26\u201330.","journal-title":"J Invest Dermatol"},{"key":"9777_CR5","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.alit.2020.07.001","volume":"70","author":"M Nakanishi","year":"2021","unstructured":"Nakanishi M, Tamagawa-Mineoka R, Arakawa Y, Masuda K, Katoh N. Dupilumab-resistant facial erythema - dermoscopic, histological and clinical findings of three patients. Allergol Int. 2021;70:156\u20138.","journal-title":"Allergol Int"},{"key":"9777_CR6","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1111\/jdv.15386","volume":"33","author":"C Goujon","year":"2019","unstructured":"Goujon C, Nicolas JF, Nosbaum A. Methotrexate in atopic eczema. Comments to: consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2019;33:e154\u20135.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"9777_CR7","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/all.14870","volume":"77","author":"T Miyano","year":"2022","unstructured":"Miyano T, Irvine AD, Tanaka RJ. A mathematical model to identify optimal combinations of drug targets for dupilumab poor responders in atopic dermatitis. Allergy. 2022;77:582\u201394.","journal-title":"Allergy"},{"key":"9777_CR8","doi-asserted-by":"publisher","unstructured":"Zinellu A, Sucato F, Piras V, Addis GM, Biondi G, Montesu MA et al. Blood cells count derived inflammation indexes as predictors of early treatment response to dupilumab in patients with moderate-to-severe atopic dermatitis. J Clin Med. 2023; 12 :2104 . https:\/\/doi.org\/10.1016\/j.alit.2020.07.001","DOI":"10.1016\/j.alit.2020.07.001"},{"key":"9777_CR9","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jaad.2023.11.067","volume":"90","author":"Z Tong","year":"2024","unstructured":"Tong Z, Zhou K, Zou Y, Wu Z, Chen J, Xue C, et al. Decoding real-world outcomes: exploring clinical features associated with efficacy in patients treated with dupilumab. J Am Acad Dermatol. 2024;90:1061\u20133.","journal-title":"J Am Acad Dermatol"},{"key":"9777_CR10","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/bjd\/ljad032","volume":"188","author":"Y Wu","year":"2023","unstructured":"Wu Y, Gu C, Wang S, Yin H, Qiu Z, Luo Y, et al. Serum biomarker-based endotypes of atopic dermatitis in China and prediction for efficacy of dupilumab. Br J Dermatol. 2023;188:649\u201360.","journal-title":"Br J Dermatol"},{"key":"9777_CR11","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","volume":"143","author":"E Guttman-Yassky","year":"2019","unstructured":"Guttman-Yassky E, Bissonnette R, Ungar B, Su\u00e1rez-Fari\u00f1as M, Ardeleanu M, Esaki H, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143:155\u201372.","journal-title":"J Allergy Clin Immunol"},{"key":"9777_CR12","doi-asserted-by":"publisher","first-page":"adv00402","DOI":"10.2340\/00015555-3751","volume":"101","author":"M De Bruin-Weller","year":"2021","unstructured":"De Bruin-Weller M, Biedermann T, Bissonnette R, Deleuran M, Foley P, Girolomoni G, et al. Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies. Acta Derm Venereol. 2021;101:adv00402.","journal-title":"Acta Derm Venereol"},{"key":"9777_CR13","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.jaad.2018.01.016","volume":"78","author":"E Guttman-Yassky","year":"2018","unstructured":"Guttman-Yassky E, Brunner P, Neumann AU, Khattri S, Pavel AB, Malik K, et al. Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial. J Am Acad Dermatol. 2018;78:872\u2013e816.","journal-title":"J Am Acad Dermatol"},{"key":"9777_CR14","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.jaci.2014.10.013","volume":"134","author":"JD Hamilton","year":"2014","unstructured":"Hamilton JD, Su\u00e1rez-Fari\u00f1as M, Dhingra N, Cardinale I, Li X, Kostic A, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2014;134:1293\u2013300.","journal-title":"J Allergy Clin Immunol"},{"key":"9777_CR15","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jaci.2020.06.012","volume":"147","author":"L M\u00f6bus","year":"2021","unstructured":"M\u00f6bus L, Rodriguez E, Harder I, St\u00f6lzl D, Boraczynski N, Gerdes S, et al. Atopic dermatitis displays stable and dynamic skin transcriptome signatures. J Allergy Clin Immunol. 2021;147:213\u201323.","journal-title":"J Allergy Clin Immunol"},{"key":"9777_CR16","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.jaci.2020.03.041","volume":"146","author":"TB Rojahn","year":"2020","unstructured":"Rojahn TB, Vorstandlechner V, Krausgruber T, Bauer WM, Alkon N, Bangert C, et al. Single-cell transcriptomics combined with interstitial fluid proteomics defines cell type-specific immune regulation in atopic dermatitis. J Allergy Clin Immunol. 2020;146:1056\u201369.","journal-title":"J Allergy Clin Immunol"},{"key":"9777_CR17","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1111\/all.15781","volume":"78","author":"Y Mitamura","year":"2023","unstructured":"Mitamura Y, Reiger M, Kim J, Xiao Y, Zhakparov D, Tan G, et al. Spatial transcriptomics combined with single-cell RNA-sequencing unravels the complex inflammatory cell network in atopic dermatitis. Allergy. 2023;78:2215\u201331.","journal-title":"Allergy"},{"key":"9777_CR18","doi-asserted-by":"publisher","unstructured":"Chen Y, Chen L, Lun ATL, Baldoni PL, Smyth GK. edgeR v4: powerful differential analysis of sequencing data with expanded functionality and improved support for small counts and larger datasets. Nucleic Acids Res. 2025; 53 :gkaf018. https:\/\/doi.org\/10.1093\/nar\/gkaf018","DOI":"10.1093\/nar\/gkaf018"},{"key":"9777_CR19","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1038\/s41596-024-01020-z","volume":"19","author":"S Xu","year":"2024","unstructured":"Xu S, Hu E, Cai Y, Xie Z, Luo X, Zhan L, et al. Using clusterprofiler to characterize multiomics data. Nat Protoc. 2024;19:3292\u2013320.","journal-title":"Nat Protoc"},{"key":"9777_CR20","doi-asserted-by":"publisher","first-page":"11938","DOI":"10.7150\/thno.49451","volume":"10","author":"S Sui","year":"2020","unstructured":"Sui S, An X, Xu C, Li Z, Hua Y, Huang G, et al. An immune cell infiltration-based immune score model predicts prognosis and chemotherapy effects in breast cancer. Theranostics. 2020;10:11938\u201349.","journal-title":"Theranostics"},{"key":"9777_CR21","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","volume":"42","author":"Y Hao","year":"2024","unstructured":"Hao Y, Stuart T, Kowalski MH, Choudhary S, Hoffman P, Hartman A, et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nat Biotechnol. 2024;42:293\u2013304.","journal-title":"Nat Biotechnol"},{"key":"9777_CR22","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41590-018-0276-y","volume":"20","author":"D Aran","year":"2019","unstructured":"Aran D, Looney AP, Liu L, Wu E, Fong V, Hsu A, et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat Immunol. 2019;20:163\u201372.","journal-title":"Nat Immunol"},{"key":"9777_CR23","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/all.14151","volume":"75","author":"A Le Floc\u2019h","year":"2020","unstructured":"Le Floc\u2019h A, Allinne J, Nagashima K, Scott G, Birchard D, Asrat S, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75:1188\u2013204.","journal-title":"Allergy"},{"key":"9777_CR24","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1016\/j.jaip.2024.08.054","volume":"12","author":"P Chokevittaya","year":"2024","unstructured":"Chokevittaya P, Jirattikanwong N, Thongngarm T, Phinyo P, Wongsa C. Factors associated with dupilumab response in atopic dermatitis: a systematic review and meta-analysis. J Allergy Clin Immunol Pract. 2024;12:3044\u201356.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"9777_CR25","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s12016-022-08934-0","volume":"62","author":"A Kychygina","year":"2022","unstructured":"Kychygina A, Cassagne M, Tauber M, Galiacy S, Paul C, Fourni\u00e9 P, et al. Dupilumab-associated adverse events during treatment of allergic diseases. Clin Rev Allergy Immunol. 2022;62:519\u201333.","journal-title":"Clin Rev Allergy Immunol"},{"key":"9777_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1468-3083.2009.03351.x","volume":"24","author":"A Lyakhovitsky","year":"2010","unstructured":"Lyakhovitsky A, Barzilai A, Heyman R, Baum S, Amichai B, Solomon M, et al. Low-dose methotrexate treatment for moderate-to-severe atopic dermatitis in adults. J Eur Acad Dermatol Venereol. 2010;24:43\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"9777_CR27","doi-asserted-by":"publisher","first-page":"139757","DOI":"10.1016\/j.ijbiomac.2025.139757","volume":"297","author":"S Peng","year":"2025","unstructured":"Peng S, Yan W, Yan Y, Tang Q, Feng H, Huang X. AP2M1 as the potential biomarker for prediction of the response of atopic dermatitis to Dupilumab therapy: Multi-omics analysis and evidence. Int J Biol Macromol. 2025;297:139757.","journal-title":"Int J Biol Macromol"},{"key":"9777_CR28","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/prot.340170405","volume":"17","author":"P Bork","year":"1993","unstructured":"Bork P. Hundreds of ankyrin-like repeats in functionally diverse proteins: mobile modules that cross phyla horizontally? Proteins. 1993;17:363\u201374.","journal-title":"Proteins"},{"key":"9777_CR29","doi-asserted-by":"publisher","first-page":"3680","DOI":"10.1038\/s41388-022-02380-0","volume":"41","author":"Y Wang","year":"2022","unstructured":"Wang Y, Zhang Y, Mi J, Jiang C, Wang Q, Li X, et al. ANKFN1 plays both protumorigenic and metastatic roles in hepatocellular carcinoma. Oncogene. 2022;41:3680\u201393.","journal-title":"Oncogene"},{"key":"9777_CR30","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0091-6749(98)70140-X","volume":"102","author":"H Toru","year":"1998","unstructured":"Toru H, Pawankar R, Ra C, Yata J, Nakahata T. Human mast cells produce IL-13 by high-affinity IgE receptor cross-linking: enhanced IL-13 production by IL-4-primed human mast cells. J Allergy Clin Immunol. 1998;102:491\u2013502.","journal-title":"J Allergy Clin Immunol"},{"key":"9777_CR31","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1084\/jem.181.4.1373","volume":"181","author":"PR Burd","year":"1995","unstructured":"Burd PR, Thompson WC, Max EE, Mills FC. Activated mast cells produce interleukin 13. J Exp Med. 1995;181:1373\u201380.","journal-title":"J Exp Med"},{"key":"9777_CR32","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00262-022-03282-6","volume":"72","author":"J Li","year":"2023","unstructured":"Li J, Peng G, Zhu K, Jie X, Xu Y, Rao X, et al. PD-1(+) mast cell enhanced by PD-1 blocking therapy associated with resistance to immunotherapy. Cancer Immunol Immunother. 2023;72:633\u201345.","journal-title":"Cancer Immunol Immunother"},{"key":"9777_CR33","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41467-020-20600-7","volume":"12","author":"R Somasundaram","year":"2021","unstructured":"Somasundaram R, Connelly T, Choi R, Choi H, Samarkina A, Li L, et al. Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy. Nat Commun. 2021;12:346.","journal-title":"Nat Commun"},{"key":"9777_CR34","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1001\/jamadermatol.2022.3014","volume":"158","author":"LS Spekhorst","year":"2022","unstructured":"Spekhorst LS, de Graaf M, Zuithoff NPA, van den Reek J, Kamsteeg M, Boesjes CM, et al. Dupilumab drug survival and associated predictors in patients with moderate to severe atopic dermatitis: long-term results from the daily practice BioDay registry. JAMA Dermatol. 2022;158:1048\u201356.","journal-title":"JAMA Dermatol"},{"key":"9777_CR35","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","volume":"20","author":"X Mao","year":"2021","unstructured":"Mao X, Xu J, Wang W, Liang C, Hua J, Liu J, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20:131.","journal-title":"Mol Cancer"},{"key":"9777_CR36","doi-asserted-by":"publisher","first-page":"109742","DOI":"10.1016\/j.clim.2023.109742","volume":"255","author":"Z Li","year":"2023","unstructured":"Li Z, Cao T, Li Q, Zhang J, Du J, Chen J, et al. Cross-disease characterization of fibroblast heterogeneities and their pathogenic roles in skin inflammation. Clin Immunol. 2023;255:109742.","journal-title":"Clin Immunol"},{"key":"9777_CR37","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/j.jaci.2020.01.042","volume":"145","author":"H He","year":"2020","unstructured":"He H, Suryawanshi H, Morozov P, Gay-Mimbrera J, Del Duca E, Kim HJ, et al. Single-cell transcriptome analysis of human skin identifies novel fibroblast subpopulation and enrichment of immune subsets in atopic dermatitis. J Allergy Clin Immunol. 2020;145:1615\u201328.","journal-title":"J Allergy Clin Immunol"},{"key":"9777_CR38","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1038\/s41388-025-03537-3","volume":"44","author":"H Tsuchiya","year":"2025","unstructured":"Tsuchiya H, Hanaki T, Sakabe T, Tokuyasu N, Nagahara T, Umekita Y, et al. Immune evasion from macrophages by NEAT1-induced CD24 in liver cancer. Oncogene. 2025;44:3652\u201364.","journal-title":"Oncogene"},{"key":"9777_CR39","doi-asserted-by":"publisher","unstructured":"Hanamura T, Kitano S, Kagamu H, Yamashita M, Terao M, Okamura T et al. Abstract P2-20-16: Hormone receptor expression is associated with specific immunological profiles in the breast cancer microenvironment. Cancer Res. 2023; 83: 2-20 https:\/\/doi.org\/10.1158\/1538-7445.SABCS22-P2-20-16","DOI":"10.1158\/1538-7445.SABCS22-P2-20-16"},{"key":"9777_CR40","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40364-024-00719-1","volume":"13","author":"XY Sui","year":"2025","unstructured":"Sui XY, Cao SW, Song XQ, Liu XY, Chen C, Yan Q, et al. MORF4L2 induces immunosuppressive microenvironment and immunotherapy resistance through GRHL2\/MORF4L2\/H4K12Ac\/CSF1 axis in triple-negative breast cancer. Biomark Res. 2025;13:6.","journal-title":"Biomark Res"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-026-09777-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-026-09777-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-026-09777-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:10:32Z","timestamp":1777601432000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-026-09777-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9777"],"URL":"https:\/\/doi.org\/10.1007\/s12026-026-09777-z","relation":{},"ISSN":["1559-0755"],"issn-type":[{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"assertion":[{"value":"23 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study followed principles outlined in the Declaration of Helsinki. Ethical approval was not required for this study in accordance with the statement of ethics committee from The First Affiliated Hospital of Guangxi Medical University .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"45"}}